Skip to main content
Premium Trial:

Request an Annual Quote

Millennium Exceeds $1B In Pharma Funding


CAMBRIDGE, Mass.--Following an alliance with Bayer, Millennium Pharmaceuticals said it has reached over $1 billion in potential pharmaceutical partnership funding. As a result, assuming the Millennium-Bayer alliance receives US Federal Trade Commission approval by year-end as anticipated, the company expects to be profitable for 1998, close the year with over $160 million in cash on-hand, and be poised to leverage its strengthened financial position to expand its drug discovery and development capabilities.

Millennium and Bayer announced that the primary goal of their alliance is for Millennium to supply 225 important new drug targets related to cardiovascular disease, cancer, osteoporosis, pain, liver fibrosis, hematology, and viral infections. Over the five-year term of the alliance, Bayer will provide up to $465 million in total funding to Millennium, including an up-front equity investment and license fee of $130 million, and an additional $335 million in a combination of license fees, annual research funding, and performance fees.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.